Literature DB >> 14598943

Postoperative chemotherapy with cisplatin and 5-fluorouracil in cancer of the oral cavity and the oropharynx--long-term results.

A F Kovács1, M T Ghahremani, U Stefenelli, K Bitter.   

Abstract

Adjuvant chemotherapy has not yet been proven to have a survival benefit for patients with head and neck cancer. Studies dealing with this topic have had several faults like mingling tumor localizations and treatment modalities. To re-examine the role of postoperative chemotherapy in oral cavity cancer, a single-center study was conducted with the attempt to have higher homogeneity. 122 patients with primary squamous cell carcinoma of the lip, the oral cavity and the oropharynx have been treated with 100 mg/m2 cisplatin bolus infusion and 120-h continuous infusion of 1000 mg/m2 5-fluorouracil following radical surgery; 99 patients completed all 3 cycles. The disease-free and overall survival are reported and compared to a control group of 161 patients with cancer of the lip, the oral cavity and oropharynx treated only with surgery, and a treatment-dependent prognostic index. After a median follow-up of 79 months (range 5-18 years), the current 5-year overall survival of the chemotherapy group was 67% and the 5-year disease-free survival was 57% while the respective data for the control group are 46% and 40%. This difference is statistically significant. The comparison with the prognostic index confirmed this result. The chemotherapy group suffered from fewer local and more neck relapses and had a much longer relapse latency (29 months versus 8 months). The toxicity of the chemotherapy regimen was tolerable. In a homogeneous population with resectable oral cavity and oropharyngeal cancer, postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil resulted in a high overall survival rate which was significantly better than in a comparable population treated only with surgery and better than the survival expectation calculated with the help of a prognostic index. A prospective randomized study of postoperative chemotherapy versus control, exclusively in patients with oral cancer, is warranted.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14598943     DOI: 10.1179/joc.2003.15.5.495

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  6 in total

1.  [Local chemotherapy for squamous cell cancer of the oral cavity and oropharynx].

Authors:  S Rohde; A F Kovács; F E Zanella; J Berkefeld; B Turowski
Journal:  Radiologe       Date:  2005-09       Impact factor: 0.635

Review 2.  Models, mechanisms and clinical evidence for cancer dormancy.

Authors:  Julio A Aguirre-Ghiso
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

3.  [Survival improvement of a unicentric overall population in 20 years: 1038 patients with oral and oropharyngeal squamous cell cancer 1983-2004].

Authors:  Adorján F Kovács; Waleed Megahed; Michael Scholz; Robert Sader
Journal:  Mund Kiefer Gesichtschir       Date:  2007-09-25

4.  Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.

Authors:  Tim Kottke; Laura Evgin; Kevin G Shim; Diana Rommelfanger; Nicolas Boisgerault; Shane Zaidi; Rosa Maria Diaz; Jill Thompson; Elizabeth Ilett; Matt Coffey; Peter Selby; Hardev Pandha; Kevin Harrington; Alan Melcher; Richard Vile
Journal:  Cancer Immunol Res       Date:  2017-10-15       Impact factor: 11.151

5.  Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence.

Authors:  Timothy Kottke; Nicolas Boisgerault; Rosa Maria Diaz; Oliver Donnelly; Diana Rommelfanger-Konkol; Jose Pulido; Jill Thompson; Debabrata Mukhopadhyay; Roger Kaspar; Matt Coffey; Hardev Pandha; Alan Melcher; Kevin Harrington; Peter Selby; Richard Vile
Journal:  Nat Med       Date:  2013-11-17       Impact factor: 53.440

6.  Long-term quality of life after intensified multi-modality treatment of oral cancer including intra-arterial induction chemotherapy and adjuvant chemoradiation.

Authors:  Adorján F Kovács; Ulrich Stefenelli; Gerrit Thorn
Journal:  Ann Maxillofac Surg       Date:  2015 Jan-Jun
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.